All stock lists
Bicara Therapeutics Inc. (NASDAQ:BCAX)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
16.82-0.25 (-1.46%)
Insider Score
––Not scored
BCAX Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
BCAX Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 14.18 M | 12.74 M | 8.13 M | 7.70 M | 7.22 M | 7.46 M |
| R&D Expense | 45.77 M | 47.50 M | 32.99 M | 5.82 M | 24.80 M | 34.33 M |
| Operating Expenses | 59.95 M | 60.24 M | 41.12 M | 40.68 M | 32.02 M | 41.79 M |
| Operating Income | -59.95 M | -60.24 M | -41.12 M | -40.68 M | -32.02 M | -41.79 M |
| Pretax Income | -55.38 M | -56.16 M | -37.33 M | -36.29 M | -27.34 M | -36.77 M |
| Tax Provision | 61.00 K | -52.00 K | 53.00 K | 40.00 K | 52.00 K | 72.00 K |
| Net Income | -55.44 M | -56.21 M | -37.39 M | -36.33 M | -27.39 M | -36.85 M |
| EPS (Basic) | -0.82 | -0.93 | -0.68 | -0.67 | -0.50 | -0.68 |
| EPS (Diluted) | -0.82 | -0.93 | -0.68 | -0.67 | -0.50 | -0.68 |
| Shares Outstanding | 67.93 M | 60.72 M | 55.14 M | 54.56 M | 54.54 M | 54.46 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.